Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | SVP, Finance & CAO | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,860 |
Ending reported balance
After 2026-10-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-05 · Exercise / conversion · Acquired 19,000 · Balance 46,860 Row 2 · 2026-10-05 · Sale · Disposed 19,000 · Balance 27,860 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.92 · Expires 2032-08-08 | Direct | 74,068 |
Reported balance
After 2026-10-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-05 · Exercise / conversion · Disposed 19,000 · Balance 74,068 F2: Stock Option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025.
F2: Stock Option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001960048-26-000013 · wk-form4_1791403671.xml · derivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,068 Underlying: Common Stock · 19,000 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock Option is fully vested and exercisable. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 19,000 | $86.74 | $1,648,060.00 |
DisclosureSEC source: 0001960048-26-000013 · wk-form4_1791403671.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,860 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 19,000 | $25.92 | $492,480.00 |
DisclosureSEC source: 0001960048-26-000013 · wk-form4_1791403671.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2026 Filed Sep 9, 2026 21:52 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,327 | $60.36 | $80,097.72 |
DisclosureSEC source: 0001960048-26-000011 · wk-form4_1788990731.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,860 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2026 Filed Sep 2, 2026 23:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 326 | $61.58 | $20,075.08 |
DisclosureSEC source: 0001960048-26-000009 · wk-form4_1788393289.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,187 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 23:54 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 243 | $60.74 | $14,759.82 |
DisclosureSEC source: 0001960048-26-000009 · wk-form4_1788393289.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,513 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. F2 · balance_after: Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001960048-26-000007 · wk-form4_1775680362.xml · derivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,068 Underlying: Common Stock · 3,000 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 3,000 | $60.00 | $180,000.00 |
DisclosureSEC source: 0001960048-26-000007 · wk-form4_1775680362.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,975 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:32 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 3,000 | $25.92 | $77,760.00 |
DisclosureSEC source: 0001960048-26-000007 · wk-form4_1775680362.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 23:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 405 | $56.26 | $22,786.52 |
DisclosureSEC source: 0001960048-26-000005 · wk-form4_1773875008.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,975 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2026 Filed Mar 18, 2026 23:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 1,487 | $55.39 | $82,360.47 |
DisclosureSEC source: 0001960048-26-000005 · wk-form4_1773875008.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,380 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $54.98 to $55.935. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001960048-26-000004 · wk-form4_1773264233.xml · derivative · entry 4 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,068 Underlying: Common Stock · 2,500 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 2,500 | $58.59 | $146,481.75 |
DisclosureSEC source: 0001960048-26-000004 · wk-form4_1773264233.xml · nonDerivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,867 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 2,500 | $25.92 | $64,800.00 |
DisclosureSEC source: 0001960048-26-000004 · wk-form4_1773264233.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:23 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 495 | $59.32 | $29,363.40 |
DisclosureSEC source: 0001960048-26-000004 · wk-form4_1773264233.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,867 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 01:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 326 | $61.98 | $20,205.48 |
DisclosureSEC source: 0001960048-26-000002 · wk-form4_1772500112.xml · nonDerivative · entry 4 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,362 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 01:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 243 | $61.98 | $15,061.14 |
DisclosureSEC source: 0001960048-26-000002 · wk-form4_1772500112.xml · nonDerivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,688 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 7,716 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001960048-26-000002 · wk-form4_1772500112.xml · derivative · entry 6 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,568 Underlying: Common Stock · 7,716 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 17,855 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001960048-26-000002 · wk-form4_1772500112.xml · derivative · entry 5 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,855 Underlying: Common Stock · 17,855 shares Expires 2036-02-26 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 26, 2026, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 7,716 | $25.92 | $199,998.72 |
DisclosureSEC source: 0001960048-26-000002 · wk-form4_1772500112.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 01:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 10,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001960048-26-000002 · wk-form4_1772500112.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, Finance & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,215 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2026 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001960048-25-000010 · wk-form4_1767048548.xml · nonDerivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,534 F2 · shares: Reflects the bona-fide gift of the Issuer's common stock to a Charitable Donor Advised Fund. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 6,716 | $47.94 | $321,931.46 |
DisclosureSEC source: 0001960048-25-000010 · wk-form4_1767048548.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,534 Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:49 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,907 | $47.90 | $235,040.39 |
DisclosureSEC source: 0001960048-25-000010 · wk-form4_1767048548.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,250 F1 · balance_after: Includes one (1) share acquired on November 17, 2025 under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| September 08, 2025 Filed Sep 10, 2025 20:28 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 482 | $32.41 | $15,621.62 |
DisclosureSEC source: 0001960048-25-000008 · wk-form4_1757536101.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,156 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 07, 2025 Filed Aug 30, 2025 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001960048-25-000006 · wk-form4_1756512492.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,205 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on March 7, 2026 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. F2 · balance_after: Includes 289 shares acquired under the Issuer's Employee Stock Purchase Plan on May 16, 2025. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 325 | $31.56 | $10,257.00 |
DisclosureSEC source: 0001960048-25-000007 · wk-form4_1757016769.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,638 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 20:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 242 | $31.56 | $7,637.52 |
DisclosureSEC source: 0001960048-25-000007 · wk-form4_1757016769.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,963 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| August 29, 2025 Filed Aug 30, 2025 00:08 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 9,743 | $0.00 Strike: $30.79 | $0.00 |
DisclosureSEC source: 0001960048-25-000006 · wk-form4_1756512492.xml · derivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,743 Underlying: Common Stock · 9,743 shares Expires 2035-08-29 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on September 29, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 02:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 325 | $72.10 | $23,432.50 |
DisclosureSEC source: 0001649094-25-000041 · wk-form4_1741054569.xml · nonDerivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,106 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 02:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 242 | $73.02 | $17,670.84 |
DisclosureSEC source: 0001649094-25-000041 · wk-form4_1741054569.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,431 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of RSUs. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 17,961 | $0.00 Strike: $74.22 | $0.00 |
DisclosureSEC source: 0001649094-25-000041 · wk-form4_1741054569.xml · derivative · entry 4 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,961 Underlying: Common Stock · 17,961 shares Expires 2035-02-26 F3 · derivative.exercise_date: 1/48 of shares subject to the option vest on March 27, 2025, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:16 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 5,379 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-25-000041 · wk-form4_1741054569.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,673 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 7, 2025 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 7,716 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001649094-24-000124 · wk-form4_1734556392.xml · derivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,284 Underlying: Common Stock · 7,716 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:13 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 7,716 | $25.92 | $199,998.72 |
DisclosureSEC source: 0001649094-24-000124 · wk-form4_1734556392.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2024 Filed Nov 9, 2024 01:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantPerformance Stock Option (right to buy) · Derivative | 11,900 | $0.00 Strike: $102.70 | $0.00 |
DisclosureSEC source: 0001649094-24-000109 · wk-form4_1731117057.xml · derivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,900 Underlying: Common Stock · 11,900 shares Expires 2034-11-06 F1 · derivative.exercise_date: As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 11,900 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)). Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001649094-24-000063 · wk-form4_1725570915.xml · derivative · entry 4 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,000 Underlying: Common Stock · 5,000 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,145 | $110.15 | $126,121.75 |
DisclosureSEC source: 0001649094-24-000063 · wk-form4_1725570915.xml · nonDerivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,578 F2 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated September 4, 2024 were sold by the Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,000 | $107.67 | $538,350.00 |
DisclosureSEC source: 0001649094-24-000063 · wk-form4_1725570915.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,723 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $25.92 | $129,600.00 |
DisclosureSEC source: 0001649094-24-000063 · wk-form4_1725570915.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2024 Filed Jul 17, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001649094-24-000036 · wk-form4_1721246588.xml · derivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 5,000 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| July 16, 2024 Filed Jul 17, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,000 | $85.00 | $425,000.00 |
DisclosureSEC source: 0001649094-24-000036 · wk-form4_1721246588.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,723 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023. Read SEC document |
| July 16, 2024 Filed Jul 17, 2024 20:03 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $25.92 | $129,600.00 |
DisclosureSEC source: 0001649094-24-000036 · wk-form4_1721246588.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001649094-24-000034 · wk-form4_1720559736.xml · derivative · entry 3 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,000 Underlying: Common Stock · 5,000 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/4 of the shares subject to the option vested on July 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 5,000 | $80.00 | $400,000.00 |
DisclosureSEC source: 0001649094-24-000034 · wk-form4_1720559736.xml · nonDerivative · entry 2 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,723 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 21:15 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 5,000 | $25.92 | $129,600.00 |
DisclosureSEC source: 0001649094-24-000034 · wk-form4_1720559736.xml · nonDerivative · entry 1 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 567 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2024. Read SEC document |
| March 02, 2024 Filed Mar 5, 2024 02:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 324 | $71.55 | $23,182.20 |
DisclosureSEC source: 0001415889-24-006475 · form4-03052024_020305.xml · nonDerivative · entry 6 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,156 F7 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0001415889-24-006475 · form4-03052024_020305.xml · derivative · entry 8 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 11,000 shares Expires 2032-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest on July 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,901 | $74.90 | $367,084.90 |
DisclosureSEC source: 0001415889-24-006475 · form4-03052024_020305.xml · nonDerivative · entry 5 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,480 F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023. F6 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $74.47 to $75.02. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:22 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,455 | $73.69 | $328,284.50 |
DisclosureSEC source: 0001415889-24-006475 · form4-03052024_020305.xml · nonDerivative · entry 4 Cowan Elvia · CIK 0001960048 · SVP, FINANCE 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,381 F3 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2023. F5 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $73.42 to $74.465. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.